David Nierengarten Analyst PerformanceManaging Director, Equity Research at WedbushDavid Nierengarten is a stock analyst at Wedbush focused in the medical sector, covering 41 publicly traded companies. Over the past year, David Nierengarten has issued 86 stock ratings, including buy and hold recommendations. While full access to David Nierengarten's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Nierengarten's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings137 Last 11 YearsBuy Recommendations77.04% 104 Buy RatingsCompanies Covered41 Unique Companies Ratings Distribution135RatingsDistribution of strong buy, buy, hold, and sell ratings by David Nierengarten.RatingPercentageCount Strong Buy0.0%0 ratings Buy77.0%104 ratings Hold23.0%31 ratings Sell0.0%0 ratingsOut of 135 total stock ratings issued by David Nierengarten at Wedbush, the majority (77.0%) have been Buy recommendations, followed by 23.0% Hold.Best & Worst CallsBest Call0000.0%BEAMMay 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%DAREApr 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ95.1% of companies on NASDAQ39 companiesNYSE2.4% of companies on NYSE1 companyNYSEAMERICAN2.4% of companies on NYSEAMERICAN1 companyDavid Nierengarten, an analyst at Wedbush, currently covers 41 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical39 companies95.1%Manufacturing1 company2.4%Miscellaneous1 company2.4%David Nierengarten of Wedbush specializes in stock coverage within the Medical sector, with additional focus on Manufacturing and companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE33 companies80.5%MED - DRUGS5 companies12.2%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company2.4%Miscellaneous1 company2.4%SURGICAL & MEDICAL INSTRUMENTS1 company2.4% About David NierengartenDavid Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy. His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models. In addition, David has results in predicting Dendreon’s looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor. David received his B.S. in Biochemistry from the University of Wisconsin-Madison, and Ph.D. in Molecular and Cell Biology from the University of California at Berkeley. David Nierengarten's Ratings History at Wedbush Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCOAGHemab Therapeutics7/13/2026Reiterated Rating$38.03$55.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics7/10/2026Boost Price Target$15.44$17.00Neutral$0.0000.00% ROITLXTelix Pharmaceuticals7/6/2026Reiterated Rating$11.87$22.00Outperform$0.0000.00% ROIABVXAbivax6/30/2026Boost Price Target$96.15$110.00Neutral$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International6/29/2026Boost Price Target$59.96$72.00Outperform$0.0000.00% ROITCRXTScan Therapeutics6/23/2026Reiterated Rating$0.87$5.00Outperform$0.0000.00% ROIAPGEApogee Therapeutics6/22/2026Downgrade$132.61$135.00Neutral$0.0000.00% ROISYRESpyre Therapeutics6/16/2026Reiterated Rating$81.95$100.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics6/15/2026Reiterated Rating$13.39$12.00Neutral$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock6/12/2026Reiterated Rating$21.51$35.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. IMNMImmunome6/12/2026Reiterated Rating$18.76$31.00Outperform$0.0000.00% ROIARGXargenex6/11/2026Reiterated Rating$882.46$1,000.00Outperform$0.0000.00% ROIIRONDisc Medicine6/10/2026Reiterated Rating$69.99$88.00Outperform$0.0000.00% ROINUVLNuvalent6/9/2026Downgrade$122.87$124.00Neutral$0.0000.00% ROIARGXargenex6/4/2026Reiterated Rating$813.14$1,000.00Outperform$0.0000.00% ROIABVXAbivax6/2/2026Upgrade$129.69$90.00Neutral$0.0000.00% ROIODTXOdyssey Therapeutics6/2/2026Initiated Coverage$16.96$30.00Outperform$0.0000.00% ROICOGTCogent Biosciences5/29/2026Reiterated Rating$35.21$55.00Outperform$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock5/28/2026Initiated Coverage$25.21$35.00Outperform$0.0000.00% ROINUVLNuvalent5/28/2026Reiterated Rating$107.38$125.00Outperform$0.0000.00% ROIAPGEApogee Therapeutics5/27/2026Boost Price Target$84.60$135.00Outperform$0.0000.00% ROICOAGHemab Therapeutics5/26/2026Initiated Coverage$25.89$42.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics5/12/2026Reiterated Rating$14.42$12.00Neutral$0.0000.00% ROISTTKShattuck Labs5/8/2026Boost Price Target$6.48$11.00Outperform$0.0000.00% ROINUVBNuvation Bio5/5/2026Reiterated Rating$4.66$11.00Outperform$0.0000.00% ROICATXPerspective Therapeutics5/5/2026Reiterated Rating$3.78$11.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/29/2026Boost Price Target$54.04$59.00Outperform$0.0000.00% ROICATXPerspective Therapeutics4/20/2026Reiterated Rating$4.20$11.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/16/2026Boost Price Target$46.31$58.00Outperform$0.0000.00% ROINVCRNovoCure4/16/2026Reiterated Rating$12.24$18.00Neutral$0.0000.00% ROINUVBNuvation Bio4/16/2026Reiterated Rating$4.83$11.00Outperform$0.0000.00% ROIFENCAdherex Technologies4/16/2026Reiterated Rating$6.50$13.00Outperform$0.0000.00% ROISYRESpyre Therapeutics4/13/2026Boost Price Target$64.47$80.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals4/13/2026Reiterated Rating$10.54$22.00Outperform$0.0000.00% ROINUVLNuvalent4/8/2026Reiterated Rating$102.25$125.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals4/7/2026Reiterated Rating$9.09$22.00Outperform$0.0000.00% ROINUVBNuvation Bio4/2/2026Reiterated Rating$4.50$11.00Outperform$0.0000.00% ROISRRKScholar Rock4/1/2026Boost Price Target$49.16$58.00Outperform$0.0000.00% ROIORICOric Pharmaceuticals4/1/2026Lower Price Target$12.67$17.00Outperform$0.0000.00% ROIBCAXBicara Therapeutics3/31/2026Reiterated Rating$19.52$30.00Outperform$0.0000.00% ROIGates. Google. The Pentagon. (Ad)Bill Gates wrote a $100 million check. Google signed a 15-year contract. The Pentagon named it their top energy priority. All three are backing the same company - and the same energy source that holds 140 times global electricity demand. Last year a drilling crew cracked through three miles of solid rock in 16 days - the government had projected 64. On August 18th, Washington is handing this technology a tax credit advantage that solar and wind no longer receive.See the company Gates, Google, and the Pentagon are all backingNUVBNuvation Bio3/27/2026Reiterated Rating$4.41$11.00Outperform$0.0000.00% ROICATXPerspective Therapeutics3/18/2026Reiterated Rating$4.95$11.00Outperform$0.0000.00% ROICOGTCogent Biosciences3/17/2026Reiterated Rating$35.68$55.00Outperform$0.0000.00% ROIARGXargenex3/9/2026Reiterated Rating$717.80$1,000.00Outperform$0.0000.00% ROISTTKShattuck Labs3/6/2026Boost Price Target$5.10$8.00Outperform$0.0000.00% ROITCRXTScan Therapeutics3/5/2026Boost Price Target$1.08$5.00Outperform$0.0000.00% ROIAPGEApogee Therapeutics3/3/2026Boost Price Target$67.77$95.00Outperform$0.0000.00% ROIBEAMBeam Therapeutics2/25/2026Boost Price Target$32.29$65.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International2/25/2026Boost Price Target$43.50$53.00Outperform$0.0000.00% ROIABVXAbivax2/24/2026Initiated Coverage$132.91$110.00Outperform$0.0000.00% ROIORICOric Pharmaceuticals2/24/2026Reiterated Rating$11.71$20.00Outperform$0.0000.00% ROIIRONDisc Medicine2/17/2026Lower Price Target$55.99$88.00Outperform$0.0000.00% ROINUVBNuvation Bio2/10/2026Reiterated Rating$5.69$11.00Outperform$0.0000.00% ROICATXPerspective Therapeutics1/30/2026Reiterated Rating$4.01$11.00Outperform$0.0000.00% ROICOGTCogent Biosciences1/21/2026Reiterated Rating$39.90$55.00Outperform$0.0000.00% ROIIRONDisc Medicine1/15/2026Reiterated Rating$72.74Outperform$0.0000.00% ROIIMNMImmunome1/15/2026Reiterated Rating$20.76$31.00Outperform$0.0000.00% ROINVCRNovoCure1/15/2026Reiterated Rating$13.77$18.00Neutral$0.0000.00% ROIARGXargenex1/14/2026Reiterated Rating$810.51$1,000.00Outperform$0.0000.00% ROIBCAXBicara Therapeutics1/13/2026Reiterated Rating$17.43$30.00Outperform$0.0000.00% ROIORICOric Pharmaceuticals1/13/2026Reiterated Rating$9.15$20.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International1/13/2026Boost Price Target$41.12$50.00Outperform$0.0000.00% ROIGBIOGeneration Bio12/16/2025Set Price Target$5.39$5.50Outperform$0.0000.00% ROIORICOric Pharmaceuticals12/8/2025Reiterated Rating$11.00$20.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International12/2/2025Reiterated Rating$40.07$48.00Outperform$0.0000.00% ROINUVLNuvalent11/17/2025Reiterated Rating$108.00$125.00Outperform$0.0000.00% ROIARGXargenex11/14/2025Boost Price Target$894.31$1,000.00Outperform$0.0000.00% ROIANABAnaptysBio11/10/2025Reiterated Rating$33.21$50.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics11/7/2025Lower Price Target$9.84$7.00Neutral$0.0000.00% ROIXNCRXencor11/6/2025Reiterated Rating$14.24$26.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics10/30/2025Set Price Target$12.37$9.00$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International10/28/2025Reiterated Rating$40.45$48.00Outperform$0.0000.00% ROIFATEFate Therapeutics10/27/2025Upgrade$1.65$7.00Outperform$0.0000.00% ROIIRONDisc Medicine10/17/2025Boost Price Target$74.36$110.00Outperform$0.0000.00% ROIANABAnaptysBio10/15/2025Boost Price Target$31.85$70.00Outperform$0.0000.00% ROIARGXargenex10/13/2025Boost Price Target$796.92$880.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International10/13/2025Boost Price Target$37.89$44.00Outperform$0.0000.00% ROINUVBNuvation Bio10/13/2025Reiterated Rating$3.73$6.00Outperform$0.0000.00% ROISTTKShattuck Labs9/8/2025Initiated Coverage$1.55$4.00Outperform$0.0000.00% ROINUVBNuvation Bio9/8/2025Reiterated Rating$3.88$6.00Outperform$0.0000.00% ROINUVLNuvalent9/8/2025Reiterated Rating$80.89$115.00Outperform$0.0000.00% ROIXNCRXencor9/2/2025Reiterated Rating$8.55$26.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals8/28/2025Reiterated Rating$12.10$22.00Outperform$0.0000.00% ROIGBIOGeneration Bio8/13/2025Downgrade$4.05$7.00Neutral$0.0000.00% ROIXNCRXencor8/7/2025Lower Price Target$7.49$26.00Outperform$0.0000.00% ROIIMAImageneBio7/25/2025Lower Price Target$16.32$23.00Neutral$0.0000.00% ROIARGXargenex6/24/2025Reiterated Rating$550.14$715.00Outperform$000.0000.00% ROICATXPerspective Therapeutics6/23/2025Reiterated Rating$3.53$11.00Outperform$0.0000.00% ROIARGXargenex6/11/2025Reiterated Rating$575.46$715.00Outperform$000.0000.00% ROINUVBNuvation Bio6/11/2025Reiterated Rating$2.14$5.00Outperform$0.0000.00% ROIMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (Ad)In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.See Jim Rickards' full market warning and what it means for your portfolioTLXTelix Pharmaceuticals6/5/2025Initiated Coverage$17.48$22.00Outperform$0.0000.00% ROIBPMCBlueprint Medicines6/2/2025Downgrade$101.15$129.00Neutral$0.0000.00% ROIITOSiTeos Therapeutics5/28/2025Downgrade$10.43$12.00Neutral$0.0000.00% ROINTLAIntellia Therapeutics5/19/2025Reiterated Rating$9.09$10.00Neutral$00.0000.00% ROINUVBNuvation Bio5/15/2025Reiterated Rating$2.24$5.00Outperform$0.0000.00% ROIBPMCBlueprint Medicines4/16/2025Reiterated Rating$79.46$128.00Outperform$0.0000.00% ROINVCRNovoCure4/16/2025Lower Price Target$15.66$27.00Neutral$00.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/16/2025Reiterated Rating$20.59$34.00Outperform$00.0000.00% ROIARGXargenex4/11/2025Reiterated Rating$577.38$715.00Outperform$000.0000.00% ROIIMNMImmunome3/20/2025Reiterated Rating$8.64$33.00Outperform$00.0000.00% ROISTROSutro Biopharma3/14/2025Downgrade$12.50$20.00Neutral$00.0000.00% ROIFATEFate Therapeutics3/6/2025Reiterated Rating$0.91$5.00Neutral$0.0000.00% ROIBCAXBicara Therapeutics2/6/2025Initiated Coverage$12.72$31.00Outperform$00.0000.00% ROIANABAnaptysBio2/3/2025Reiterated Rating$17.27$40.00Outperform$00.0000.00% ROIBPMCBlueprint Medicines1/13/2025Reiterated Rating$93.42$124.00Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyRoyal Bank Of CanadaWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftRaymond James Financial Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
